We’re beating heart disease

Summary

The FDA approved enlicitide, a pill lowering dangerous cholesterol by nearly 60%. This represents significant progress against heart disease, the leading cause of death. Advances in understanding LDL cholesterol, PCSK9 gene mutations, and new treatments like gene editing and GLP-1s are contributing to this decline.

Key Takeaways

1. Heart disease has been the leading cause of death in the United States for essentially a century, and in 2025 it killed 694,708 Americans — about one in five deaths — more than every form of cancer combined.
2. In the US, the age-adjusted death rate from cardiovascular disease has fallen about three-quarters since 1950.
3. The Food and Drug Administration (FDA) approved a small pill called enlicitide. It is a tablet you swallow once a day on an empty stomach with a sip of black coffee, water, or tea. But it does something that until now took a needle and a specialist’s prescription: It lowers the most dangerous kind of cholesterol by nearly 60 percent, about as much as the strongest injectable drugs on the market.

Statement Breakdown

• Claimed Facts: 60% of statements the article presents as facts
• Opinions: 30% of statements classified as editorial or subjective
• Claims: 10% of statements surfaced for additional reader evaluation

Credibility & Bias Reasoning

Credibility assessment: The article cites scientific findings and regulatory approvals, referencing specific studies and genetic research. It acknowledges limitations and ongoing research, demonstrating a balanced approach to presenting medical advancements.

Bias assessment: Optimistic Medical Progress. The article frames medical advancements in a highly positive and forward-looking manner, emphasizing progress and potential. While grounded in facts, the narrative consistently highlights successes and future possibilities in combating heart disease.

Note: This article highlights significant medical advancements in combating heart disease, emphasizing progress and future potential. While factual, it leans towards an optimistic portrayal of medical breakthroughs.

Credibility flag: Progressive Outlook

Claimed Facts (10)

• This is a factual statement about a regulatory approval.
• This states a quantifiable effect of the approved medication.
• This provides a statistical fact about mortality rates.
• This presents a global statistic on cardiovascular disease mortality.
• This is a factual statement about a historical trend in death rates.
• This provides a specific percentage decrease in heart attack deaths.
• This is a factual definition of LDL cholesterol.
• This states a historical fact about scientific inquiry.
• This is a factual statement about a genetic discovery.
• This presents specific statistical findings from genetic research.

Opinions (10)

• This is a subjective interpretation by the author, framing the significance of the pill.
• This is an interpretive statement by the author, framing the pill within a broader narrative of progress.
• While factually correct that heart disease is deadly, the phrasing 'that thing' and its placement as the 'deadliest thing' is a stylistic choice by the author.
• This is an interpretation and simplification of statistical data for illustrative purposes.
• This is a broad statement about the current capabilities of medical treatment, framed as a significant change.
• The word 'proved' suggests a definitive conclusion, which can be an interpretation of scientific findings.
• The phrase 'simply born with' adds a narrative element to the genetic predisposition.
• This describes limitations of statins, which is factual, but the phrasing 'don't get their LDL low enough' is a qualitative assessment.
• This is an interpretive statement about the intended use and benefits of enlicitide.
• This is a forward-looking statement and an opinion on the potential of gene editing.

Claims (5)

• The claim that GLP-1s 'will make a significant dent in heart disease' is a strong assertion that requires more direct evidence presented in the article to be fully substantiated, especially given the nuance of ongoing research.
• This statement, while cautious, implies a potential gap in proof that could be interpreted as a doubt about the drug's ultimate efficacy, even though the article later mentions injectable versions have shown such proof.
• This is a generalization that, while intuitively appealing, oversimplifies the complex factors determining treatment effectiveness.
• The term 'perversely' introduces a subjective and somewhat dramatic interpretation of a complex epidemiological shift.
• Framing the rise in obesity and related conditions as 'the reverse of progress' is a strong, potentially alarmist, and subjective interpretation.

Key Sources

• Food and Drug Administration (FDA) — Regulatory Agency
• Bryan Walsh — Author
• Helen Hobbs — Geneticist
• Jonathan Cohen — Geneticist